FindTrial
Sign In

Clinical study of mensenchymel stem cells in the prevention of graft vervus host disease

Clinical study of mensenchymel stem cells in the prevention of graft vervus host disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100049094
Enrollment
Unknown
Registered
2021-07-20
Start date
2010-01-01
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SAA, Leukemia, MDS

Interventions

MSC group:co-infusion of MSC 1*106/kg with HSC
NO-MSC group:NO

Sponsors

Department of Hematology, Medical center of Air Force, PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 56 Years

Inclusion criteria

Inclusion criteria: 1. Haplo-HSCT patients suffered from SAA,MDS or leukemia; 2. between the ages of 1-60 years old, male or female; 3. No serious organ dysfunction; 4. non HLA matched donor; 5. with follow-up conditions.

Exclusion criteria

Exclusion criteria: 1. major organ dysfunction; 2. tumor and the serious infectious diseases; 3. severe active infection; 4. others not suitable for Haplo-HSCT.

Design outcomes

Primary

MeasureTime frame
acute GHVD;chronic GVHD;—

Secondary

MeasureTime frame
relapse;Overall survival;Security;Platelet engraftment rate;Neutrophil engratmeng;lymphocyte subset;—

Countries

China

Contacts

Public ContactHengxiang Wang

Department of Hematology, Medical center of Air Force, PLA

wanghengxiangkz@sina.com+86 15611161119

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026